CANALIA surveillance

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223722

Enrollment

750

Registered

2017-11-17

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Investigational product Nonproprietary name: Canalia Combination Tablets (Teneligliptin Hydrobromide Hydrate/Canagliflozin Hydrate) Drug/investigational product: teneligliptin/canagliflozin Therapeuti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First time user of this drug in accordance with the indication for type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Patients contraindicated for administration of this drug

Design outcomes

Primary

Measure	Time frame
(1)Occurrence of ADRs, (2) HbA1c, (3) Adherence (1)Influence of patient background factors on adverse reaction profile (Type and timing of onset, incidence and incidence based on person-time method) and risk of onset of adverse reactions (2)Change in HbA1c (3)Changes in Adherence	—

Countries

Japan

Contacts

Public ContactMamoru Hoshi

Mitsubishi Tanabe Pharma Corporation

mtpc-pms-ml@ml.mt-pharma.co.jp+81-662055223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026